HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business (Health)

Set Alert for Business {Health}

Takeda Offloads Emerging Market OTCs to Acino

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 
Deals Emerging Markets Business Strategies

Tylenol Relieves Pain For J&J Consumer As Baby Care Relaunch Loses Steam

Tylenol brand boosts J&J US OTC sales 8.4% to $477m, helping balance a 24.1% decline in baby care sales due to restocking reformulated Johnson’s Baby line in 2018, mostly in the US. Firm reports consumer health sales in the US were up 1.7% to $1.39bn.
OTC Drugs Sales & Earnings Commercial

French OTC Industry Warns Over-Regulation Is Threatening Its Future

Plans to move ibuprofen, aspirin and paracetamol OTCs behind the counter in French pharmacies will harm the country's self-medication industry, which is already lagging behind its European neighbors, warns local association Afipa.
France OTC Drugs Regulation

Deals

Set Alert for Deals {Health}

Latest From Health & Deals

Edgewell Without Harry’s: Strategic Path Remains The Same, Just A Longer Road Now

One week after the FTC challenged the deal as anticompetitive, Edgewell announced on 10 February that it has terminated its merger agreement with direct-to-consumer upstart Harry’s. The firm remains focused on improving its underlying business and says its first-quarter results, posted the same day, show that its strategy is working.

Business Strategies M & A

Colgate Says Hello To Subscription-Delivery Wtih Oral Care Line Acquisition

Colgate agrees to purchase Hello Products direct-to-consumer oral care brand, complementing  its Colgate brand and its Tom’s of Maine natural-positioned line. The firm will pay with a combination of cash and debt in the deal expected to close no later than the end of February.

M & A OTC Drugs

Neuraxpharm Underlines OTC Ambitions With Easypharm Acquisition

Austria's Easypharm has been snapped up by Neuraxpharm, which is looking to take a larger slice of Europe's consumer healthcare market.
Austria Germany
See All

Strategy

Set Alert for Business Strategy {Health}

Latest From Health & Business Strategies

CBD Lotion Firm’s ‘FDA Certified’ Claim For 'OTC Drug' Is Certifiably Noncompliant

In addition to CBD, Elixicure is formulated with OTC external analgesics monograph ingredients camphor and menthol, But CBD isn't a monograph drug nor approved for use in any pharmaceutical product other than GW Pharmaceutical's Epidiolex.

Dietary Supplements OTC Drugs

Edgewell Without Harry’s: Strategic Path Remains The Same, Just A Longer Road Now

One week after the FTC challenged the deal as anticompetitive, Edgewell announced on 10 February that it has terminated its merger agreement with direct-to-consumer upstart Harry’s. The firm remains focused on improving its underlying business and says its first-quarter results, posted the same day, show that its strategy is working.

Business Strategies M & A

Prestige Consumer Healthcare Grows International Sales 8%, Citing Hydralyte Expansion

Prestige Consumer Healthcare’s Hydralyte sales grew in excess of 20% fiscal year-to-date in key market Australia, reflecting PCH’s work to expand the brand’s appeal from a vomiting and diarrhea treatment to a sports and general hydration drink. Hydralyte is PCH’s biggest brand in Australia where the name is “synonymous with oral hydration,” company leadership says.

Health Sales & Earnings
See All

Sales & Earnings

Set Alert for Sales & Earnings {Health}

Latest From Health & Sales & Earnings

Edgewell Without Harry’s: Strategic Path Remains The Same, Just A Longer Road Now

One week after the FTC challenged the deal as anticompetitive, Edgewell announced on 10 February that it has terminated its merger agreement with direct-to-consumer upstart Harry’s. The firm remains focused on improving its underlying business and says its first-quarter results, posted the same day, show that its strategy is working.

Business Strategies M & A

Prestige Consumer Healthcare Grows International Sales 8%, Citing Hydralyte Expansion

Prestige Consumer Healthcare’s Hydralyte sales grew in excess of 20% fiscal year-to-date in key market Australia, reflecting PCH’s work to expand the brand’s appeal from a vomiting and diarrhea treatment to a sports and general hydration drink. Hydralyte is PCH’s biggest brand in Australia where the name is “synonymous with oral hydration,” company leadership says.

Health Sales & Earnings

Sanofi Looks To Future After Difficult 2019

With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
Sales & Earnings Business Strategies
See All

Litigation

Set Alert for Legal Issues {Health}

Latest From Health & Legal Issues

FDA Preemption Comment Could Sway California Against Prop 65 Warnings For Acetaminophen

 Food and drug attorneys suggest it is unlikely California will require Prop 65 warnings on OTC acetaminophen products after FDA tells the state that warnings would violate federal regulations. FDA also says sciences doesn't support a conclusion acetaminophen can cause cancer and that the warnings would confuse consumers.
OTC Drugs State News

French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
France OTC Drugs

Potential Pediatric Acetaminophen Label Changes Resurface In Tylenol Class Action Settlement

Settlement could be another milestone in the contentious history of labeling for OTC acetaminophen single-ingredient products generally, and for infant’s and children’s products specifically. Plaintiffs alleged they were misled by J&J to pay more for Infant's Tylenol even though its formulation is the same as Children's Tylenol.

OTC Drugs Pediatrics
See All
UsernamePublicRestriction

Register